Accelerator-Free Nitrile Gloves: Checking the Supplier's Claim

When clinical staff report persistent hand irritation, hospital buyers and distributors are often asked to quote an accelerator-free nitrile examination glove. A department wants to leave the current nitrile SKU because of dermatitis complaints, and the vendor offers an accelerator-free glove as the replacement. Accelerator-free is a supplier formulation claim, not an FDA-defined performance class or clearance category. FDA clears nitrile patient examination gloves as Class I reserved devices under 21 CFR 880.6250 on water-leak testing, ASTM D6319 physicals, and ISO 10993 biocompatibility endpoints. None of those tests measures whether chemical accelerators are absent.

Before the SKU changes, treat accelerator-free as a testable material specification. Ask for four records: (1) a written formulation statement naming which accelerator classes are excluded and what cross-linking chemistry replaces them; (2) a dated residual-accelerator report, for example ASTM D7558-09(2024), with the detection limit and the unit the method actually reports; (3) the 510(k) number, regulation, and product code, so the claim is not confused with the clearance; and (4) a quality-agreement notice clause that requires written notice before a compounding or manufacturing change ships. A documented accelerator-free claim is aimed at Type IV allergic contact dermatitis from residual vulcanization chemicals. It does not address irritant contact dermatitis from hand hygiene, alcohol rubs, friction, or sweating inside an occlusive glove.

To evaluate an accelerator-free claim, procurement professionals must first understand the polymer chemistry of nitrile glove manufacturing. Synthetic nitrile rubber is an acrylonitrile-butadiene copolymer. In the uncured nitrile emulsion, the polymer chains are dispersed and do not yet form an elastic film. Linking those chains is called vulcanization.

In conventional nitrile glove compounding, vulcanization is achieved using elemental sulfur cross-linking. Because sulfur reacts slowly on its own, chemical catalysts known as rubber vulcanization accelerators are added to the dip tank. Accelerators speed up the chemical reaction, lower the required curing temperature, and enable automated manufacturing lines to operate at high production speeds. The primary accelerator chemical families used across the disposable glove industry include:

• Dithiocarbamates: Such as zinc dibutyldithiocarbamate (ZDBC), zinc diethyldithiocarbamate (ZDEC), and zinc dimethyldithiocarbamate (ZDMC). These are ultra-accelerators that rapidly facilitate cross-linking during initial heating.

• Thiurams: Such as tetramethylthiuram disulfide (TMTD) and tetraethylthiuram disulfide (TETD). These compounds act as both accelerators and secondary sulfur donors during vulcanization.

• Mercaptobenzothiazoles: Such as 2-mercaptobenzothiazole (MBT) and zinc mercaptobenzothiazole (ZMBT). These thiazole derivatives serve as primary semi-ultra accelerators.

• Guanidines: Including diphenylguanidine, this family appears in rubber-chemical taxonomies. The public scope of ASTM D7558, discussed below, does not cover every family outside the three classes it names.

Not every accelerator molecule is consumed in the cure. Residual accelerator can remain in the finished film. The American Academy of Allergy, Asthma and Immunology describes allergic contact dermatitis to nitrile gloves as usually due to rubber accelerators used to make them, including thiurams, dithiocarbamates, and mercaptobenzothiazole, rather than the nitrile polymer itself. That is a purchasing distinction: the claim is about those added chemicals, not about a different FDA device class.

An accelerator-free claim says the supplier replaced the sulfur-accelerator system with some other cure. Suppliers describe examples such as ionic cross-linking, metal-oxide bonding, or peroxide systems. Those are questions to ask of this SKU. They are not a category-wide recipe, and the words on the box do not establish which cure was used.

The table below summarizes the key material, chemical, and regulatory differences between conventional nitrile examination gloves and accelerator-free formulations:

A 510(k) clearance letter is not government verification of a marketing claim. Separate the clearance from the selling copy. Non-powdered patient examination gloves, including natural rubber, polychloroprene, and nitrile, are regulated under 21 CFR 880.6250. FDA describes medical gloves as Class I reserved devices that require a 510(k). Under 880.6250, only a finger cot is exempt from premarket notification, and that exemption is limited by 21 CFR 880.9. Product code LZA is the code used for a nitrile (polymer) patient examination glove, as in the cleared summaries K221169 and K143477. It is not the product code for every material under 880.6250. Some chemotherapy-tested nitrile exam gloves also carry an additional code, such as LZC on K200181. That extra code still does not test accelerator content.

The cited nitrile exam-glove summaries document four areas. None of them is accelerator content:

1. Water-leak integrity: 21 CFR 800.20 sets a 1,000 mL water-fill method and treats 2.5 AQL as the minimum acceptable leak quality for patient examination gloves. FDA's own sampling plan in that section uses general inspection level II. Cleared summaries such as K143477 also cite ASTM D5151 and an AQL of 2.5. The test looks for holes. It does not measure accelerators. A tighter AQL, such as 1.5, is still within that leak rule; it is not evidence about cure chemistry.

2. ASTM D6319 physicals: The summaries report length, width, thickness, tensile strength, and elongation before and after aging against ASTM D6319. Those are strength and dimension checks.

3. Residual powder: The summaries report a residual-powder result, often against ASTM D6124. FDA's medical-glove page describes the December 19, 2016 final rule that banned powdered gloves. A powder result supports the non-powdered identification. It says nothing about accelerators.

4. ISO 10993 endpoints actually printed in the summaries: K221169 and K143477 report irritation and sensitization under ISO 10993-10, and K221169 also reports ISO 10993-5 cytotoxicity and ISO 10993-11 systemic toxicity. Record the endpoint the summary prints, and stop there.

The sensitization line is not a chemical assay. K221169 reports dermal sensitization as "not a sensitizer" under the conditions of the study. K143477 reports dermal sensitization under ISO 10993-10 as non-sensitizer, and primary skin irritation as not an irritant under the conditions of the study. K221169 also reports ISO 10993-5 cytotoxicity as cytotoxic under the conditions of the study. A cleared file can contain a cytotoxicity finding. Neither sentence identifies or quantifies accelerators. A sensitization pass does not mean the glove was made without dithiocarbamates, thiurams, or mercaptobenzothiazoles. For the family-level map of exam and surgical glove classification, leak testing, and the powder ban, see medical exam and surgical glove specifications.

When reviewing product cut sheets, distributor tenders, and packaging samples, procurement specialists should scrutinize claim language for regulatory hygiene. One of the clearest indicators of marketing rhetoric masquerading as technical specification is the appearance of the word 'hypoallergenic'.

21 CFR 801.437(h), from the final rule published in the September 30, 1997 Federal Register and effective September 30, 1998, states that devices containing natural rubber that contacts humans shall not contain the term "hypoallergenic" on their labeling. The rule's rationale is that the word incorrectly implies a latex-sensitive person can use the product safely. FDA's Medical Glove Guidance Manual, issued January 22, 2008, says FDA strongly discourages the term "hypoallergenic" because it cannot be scientifically defined or quantified, and discourages it for any medical device, whether or not the device contains natural rubber latex. The same manual lists "Accelerator Free" among examples of claims that may misbrand a glove when the labeling is exaggerated, untrue, or unsubstantiated under section 502(a). That is not a statutory ban on the words, and the manual states that FDA guidance does not create legally enforceable responsibilities. FDA's guidance page also says this manual has not been updated for the December 19, 2016 powdered-glove ban. Use it as a claim-language screen, not as a current powder or quality-system rule.

Beyond 'hypoallergenic', buyers should actively screen out other unverified marketing assertions from vendor proposals:

• Absolute allergy wording: Phrases such as "allergy-proof" or "zero allergy risk" run into the same problem as "hypoallergenic." The 2008 glove manual says there is virtually no way to rule out allergies to any substance. None of the clearance files cited here supports a zero-risk claim.

• "Low dermatitis potential": If the phrase appears, ask whether it is in the cleared labeling and which test the 510(k) summary actually reports. Do not fill in a study design the summary does not name. Shield Scientific's newsletter, cited below, noted gloves carrying low-dermatitis or low-residual wording without a published result the newsletter could show. The phrase is not an accelerator measurement.

• "Latex-free" is not "accelerator-free": A nitrile exam glove is not a natural rubber latex glove. Calling it latex-free restates the polymer. It does not show that accelerators were left out of the cure.

If FDA 510(k) clearance letters, ISO 10993 biocompatibility summaries, and 'hypoallergenic' marketing labels do not verify an accelerator-free claim, what evidence actually does? Sourcing teams must evaluate quotes against recognized analytical test standards designed specifically to quantify extractable vulcanization chemicals.

ASTM D7558-09(2024) is a published colorimetric/spectrophotometric method. Its public scope is to quantify total extractable accelerators in natural rubber latex and nitrile gloves. The scope names three classes: mercaptobenzothiazole, thiuram, and thiocarbamate. If the specific accelerator is not known, quantification is based on zinc dibutyldithiocarbamate (ZDBC) equivalents. The same public scope says the method will not detect all potential rubber accelerators, including mercaptobenzothiazole disulfide, dimorpholine, thioureas, and diphenyl diamine. It is a screen a buyer can request. It is not part of the 510(k) evidence in K221169 or K143477.

Summit Glove's InterceptFree specification sheet, dated February 2, 2024, is an example of method-level wording, not a ranking and not a result. The sheet describes the material as nitrile that is accelerator-, sulfur-, and zinc-free, and it lists ASTM D7558-09 for extractable accelerators next to ASTM D6124 residual powder and ASTM D6978 chemotherapy-permeation testing. It also states manufacture under GMP, ISO 9001, and ISO 13485. The sheet does not publish a measured accelerator value, a detection limit, or the laboratory's name. A line that names D7558 is not a "not detected" report.

However, technical buyers must also understand the method limitations of ASTM D7558:

• Three classes, often as ZDBC equivalents: The public scope quantifies total extractable mercaptobenzothiazole, thiuram, and thiocarbamate accelerators. When the specific accelerator is unknown, the result is in ZDBC equivalents. That is not speciation of every residue, and it is not proof that sensitizers outside those classes are absent.

• Named exclusions and reaction products: The public scope says the method does not detect every rubber accelerator, including mercaptobenzothiazole disulfide, dimorpholine, thioureas, and diphenyl diamine. CEDMC, the adduct in the 2024 case report below, is not one of the three named classes. A D7558 report cannot be stretched to cover it.

• Detection limit as reported: "Not detected" is not interpretable without the detection limit and the unit the laboratory used. Record the limit and unit the report states. The Copenhagen survey below reported milligrams per gram by HPLC, which is a different method from D7558.

For gloves bought against European single-use glove standards, a secondary explainer of EN 455-3:2023 (Eastwest Medico) describes the 2023 edition as superseding the 2015 edition. It says manufacturers must assess biological risks from materials and from processing chemicals that remain, and must list chemicals intentionally added or known to remain in the finished glove, in line with EN ISO 10993-1:2020. Ask for that chemical list and for the data behind any accelerator-free wording. Confirm any clause against the purchased standard before it goes into a tender. The same page also names EN 455-5:2025 for extractable chemical residues; confirm that document before writing it into a tender as a requirement.

Recent chemical analyses are the reason a label is not the file. They are market and case evidence, not a rule that every accelerator-free claim is false.

Larsen and colleagues (Contact Dermatitis, PMID 39367740) measured disposable rubber gloves from the Copenhagen market by high-performance liquid chromatography. The open abstract reports:

• 43 of 48 disposable gloves (90%) contained rubber accelerators. Thiurams were not identified in that set. Absence of thiurams was not absence of accelerators.

• ZDBC was in 39 gloves (81%) at 0.18–1.96 mg/g, and ZDEC was in 34 gloves (71%) at 0.032–2.78 mg/g. The same analysis found zinc dibenzyldithiocarbamate in three gloves (0.65–1.4 mg/g), zinc dimethyldithiocarbamate in one (0.23 mg/g), 1,3-diphenylguanidine in one (0.21 mg/g), and CEDMC in three gloves (below 0.052 mg/g). These are milligrams per gram from one regional sample. They are not a pass/fail number for a tender.

• The one glove labelled accelerator-free contained ZDBC at 1.07 mg/g. The authors conclude that gloves labelled accelerator-free may still contain rubber accelerators and that full labeling is needed. One labelled glove in one city is not a finding about every brand. It is enough to refuse a label that arrives without a report.

Shield Scientific, a glove supplier, reached a narrower caution in its newsletter "How accelerator-free are your accelerator-free gloves?" Its copyright notice includes 2007 and 2011, and the version line reads 2016, so it is older than the 2024–2025 chemical studies. The authors tested three accelerator-free gloves and wrote that accelerator-free gloves "may not be entirely accelerator-free," while also saying the range and the levels of accelerators appeared lower. Their explanation is analytical: aqueous HPLC can miss families that acetone extraction and thin-layer chromatography still detect. In that set, thin-layer chromatography of an acetone extract found methyl accelerator fragments in one nitrile sample and ethyl fragments in another. Read it as a supplier's warning about method gaps in a sample of three.

Silic and colleagues (Contact Dermatitis, PMID 38602297) identified 2-cyanoethyl dimethyldithiocarbamate (CEDMC) in nitrile gloves. The abstract describes two patients. HPLC found CEDMC in a nitrile glove associated with hand eczema in the first. The second patient, whose nitrile gloves contained CEDMC, was patch-test positive to CEDMC. The authors conclude that CEDMC probably forms during vulcanization from residual acrylonitrile monomer and rubber additives. The paper's background says some patients with accelerator allergy do not tolerate accelerator-free gloves and might also be patch-test positive to them. The paper title places the allergen in accelerator-free nitrile gloves. That is case evidence. It does not show that every person with an accelerator allergy will react to every accelerator-free glove. On its public scope, a three-class D7558 screen is not a CEDMC assay.

Crepy and colleagues (Contact Dermatitis, 2018, DOI 10.1111/cod.12860) followed nine healthcare workers with hand eczema and a diagnosis of allergic contact dermatitis from rubber accelerators. After a switch from conventional single-use gloves to accelerator-free medical gloves, all nine improved, and more than two-thirds were completely free of symptoms. The paper is a small occupational case series, not a controlled trial, and it does not publish residual-accelerator measurements for the replacement gloves. It supports a limited purchasing point: when the problem is accelerator allergy and the replacement is in fact low in those accelerators, symptoms can improve. A catalog phrase does not carry that result by itself.

To translate these technical, regulatory, and chemical principles into daily procurement practice, hospital purchasing committees and distributor sourcing teams should embed a standardized five-tier audit checklist into every request for quotation (RFQ) and tender specification.

The following decision workflow illustrates the step-by-step evaluation process procurement teams should execute upon receiving an accelerator-free nitrile glove quotation:

flowchart TD
    A["Supplier quotes an accelerator-free nitrile exam glove"] --> B["Read the 510(k): regulation, K-number, and product code"]
    B --> C{"Cleared exam glove under 21 CFR 880.6250?"}
    C -- "No" --> D["Do not treat the quote as a cleared exam glove"]
    C -- "Yes" --> E["Ask which accelerator classes are excluded and which cure replaces them"]
    E --> F["Ask for a dated residual test, its scope, detection limit, unit, and lab"]
    F --> G{"Does that report cover the classes named in the claim?"}
    G -- "No or missing" --> H["Do not accept accelerator-free as a specification"]
    G -- "Yes" --> I["Reject hypoallergenic and other undefined allergy wording"]
    I --> J["Require written notice before a formulation or site change ships"]
    J --> K["Qualify the SKU on the documents"]

Change control is what keeps a test result attached to later lots. Contract dipping can change the polymer source, the stabilizer package, or the cure. FDA's Quality Management System Regulation applies to the device manufacturer, not automatically to the hospital or the distributor that buys the glove. ISO 13485:2016 clause 7.4.2 is a purchasing-information requirement for organizations that use that standard. The buyer's instrument is the contract described in quality agreements for consumable suppliers: written notice before a change in formulation, additives, or manufacturing site ships. If the buyer needs a stated number of days, write that number into the agreement. Receiving should also match the device identifier and lot on the carton to the qualified SKU, as covered in UDI and GUDID capture for medical consumables.

The decision is whether the file supports the adjective. A 510(k), a water-leak result, and an ISO 10993 sensitization line can all be in order while accelerators are still in the film. ASTM D7558 can support the claim only inside its three-class scope, and only when the report states a result and a detection limit. In the Copenhagen survey, the one glove labelled accelerator-free still contained ZDBC at 1.07 mg/g. Ask for the records before the SKU changes. The records do not diagnose a skin complaint and do not guarantee that a switch will clear it.